Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues.
TLDR
In this paper, a review of the development and use of JAK inhibitors in COVID-19, from artificial intelligence to current clinical evidence, including real world experience, and critically appraise emerging safety issues, namely infections, thrombosis, and liver injury.Citations
More filters
Journal ArticleDOI
Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets.
Masoumeh Farahani,Zahra Niknam,Leila Mohammadi Amirabad,Nasrin Amiri-Dashatan,Mehdi Koushki,Mohadeseh Nemati,Fahima Danesh Pouya,Mostafa Rezaei-Tavirani,Yousef Rasmi,Lobat Tayebi +9 more
TL;DR: In this article, a review of the possible mechanisms of the host response following SARS-CoV-2 infection and surveyed current research conducted by in-vitro, in vivo and human observations, as well as existing suggestions.
Journal ArticleDOI
Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets
TL;DR: In this paper , a review of the possible mechanisms of the host response following SARS-CoV-2 infection and surveyed current research conducted by in vitro, in vivo and human observations, as well as existing suggestions.
Journal ArticleDOI
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper
Thomas Marjot,Christiane S. Eberhardt,Tobias Boettler,Luca S. Belli,Marina Berenguer,Maria Buti,Rajiv Jalan,Mario U. Mondelli,Richard Moreau,Daniel Shouval,Thomas Berg,Markus Cornberg +11 more
TL;DR: The European Association for the Study of the Liver as mentioned in this paper provides a summary of the latest data on the impact of COVID-19 on the liver and issues guidance on the care of patients with chronic liver disease, hepatobiliary cancer, and previous liver transplantation.
Journal ArticleDOI
JAK inhibitors and COVID-19
TL;DR: Whether a class effect of JAKi may be emerging in COVID-19 treatment, although at the moment the convincing data are for baricitinib only is discussed, because the precise timing of treatment will be very important in future trials.
Journal ArticleDOI
JAK-STAT Pathway: A Novel Target to Tackle Viral Infections
TL;DR: In this article, the authors review the diversity of strategies that viruses have evolved to interfere with JAK-STAT signaling, stressing the relevance of this pathway as a putative antiviral target.
References
More filters
Journal ArticleDOI
Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol
Enrico Capochiani,Bruno Frediani,Giorgio Iervasi,Aldo Paolicchi,Spartaco Sani,Paolo Roncucci,Annarosa Cuccaro,Federico Franchi,Federico Simonetti,Davide Carrara,Ilaria Bertaggia,Daniela Nasso,Rossella Riccioni,Sabino Scolletta,Serafina Valente,Edoardo Conticini,Alessandro Gozzetti,Monica Bocchia +17 more
TL;DR: In a case series of 18 critically ill patients with COVID-19 and ARDS, administration of ruxolitinib resulted in a clinical improvement that concurred to modify the standard course of disease and can be a therapeutic option for patients with respiratory insufficiency in COVID19 related ARDS.
Journal ArticleDOI
JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.
TL;DR: In this article, the authors analyzed reports on safety and efficacy of JAK-inhibitors in patients with coronavirus infectious disease-2019 (COVID-19) published between January 1st and March 6th 2021 using the Newcastle-Ottawa and Jadad scales for quality assessment.
Journal ArticleDOI
Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled.
Delia Goletti,Fabrizio Cantini +1 more
TL;DR: The clinical course of coronavirus disease 2019 (Covid-19) is characterized by an initial stage with mild symptoms of the upper respiratory tract as discussed by the authors, during this stage, the viral load of severe acute...
Journal ArticleDOI
Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study.
Ayu S. Muhamad,José Rosas,Francisco Pasquau Liaño,Mónica Llombart Cantó,José María Carrasco Barea,Amparo Raga Beser,José Tomás Algado Rabasa,Francisco Martínez Adsuar,Brian Vila Auli,Isabel Fernández López,Ana María Garijo Sainz,Pere Esquerdo Ramis,Laura Ruiz Pérez,Mª Luisa Navarrete Rebollo,Raquel Hernández Lorido,Laura Gómez Escolar +15 more
TL;DR: Treatment with BARI and TCZ did not cause serious side effects and could be considered early in patients with NI secondary to COVID19 and impaired PaO2/PaFi.
Journal ArticleDOI
Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports.
TL;DR: The use of ruxolitinib in patients with COVID-19 has given unexpected results andJanus kinase (JAK) inhibitors may be associated with a major incidence of side effects in CO VID-19 patients.